Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Van Assche, G.; Sandborn, W. J.; Feagan, B. G.; Salzberg, B. A.; Silvers, D.; Monroe, P. S.; Pandak, W. M.; Anderson, F. H.; Valentine, J. F.; Wild, G. E.; Geenen, D. J.; Sprague, R.; Targan, S. R.; Rutgeerts, P.; Vexier, V.; Young, D.; Shames, R. S.
November 2006
Gut;Nov2006, Vol. 55 Issue 11, p1568
Academic Journal
Background: An uncontrolled pilot study demonstrated that daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), might be effective for the treatment of active ulcerative colitis. Methods: A randomised, double blind, placebo controlled trial was conducted to evaluate the efficacy of daclizumab induction therapy in patients with active ulcerative colitis. A total of 159 patients with moderate ulcerative colitis were randomised to receive induction therapy with daclizumab 1 mg/kg intravenously at weeks 0 and 4, or 2 mg/kg intravenously at weeks 0, 2, 4, and 6, or placebo. The primary end point was induction of remission at week 8. Remission was defined as a Mayo score of 0 on both endoscopy and rectal bleeding components and a score of 0 or 1 on stool frequency and physician's global assessment components. Response was defined as a decrease from baseline in the Mayo score of at least 3 points. Results: Two per cent of patients receiving daclizumab 1 mg/kg (p = 0.11 v placebo) and 7% of patients receiving 2 mg/kg (p=0.73) were in remission at week 8, compared with 10% of those who received placebo. Response occurred at week 8 in 25% of patients receiving daclizumab 1 mg/kg (p=0.04) and in 33% of patients receiving 2 mg/kg (p=0.30) versus 44% of those receiving placebo. Daclizumab was well tolerated. The most frequently reported adverse events in daclizumab treated patients compared with placebo treated patients were nasopharyngitis (14.6%) and pyrexia (10.7%). Conclusion: Patients with moderate ulcerative colitis who are treated with daclizumab are not more likely to be in remission or response at eight weeks than patients treated with placebo.


Related Articles

  • NICE gives positive signal to first biologic for UC.  // Gastrointestinal Nursing;Dec2014/Jan2015, Vol. 12 Issue 10, p2 

    The article reports on the positive draft guidance issued by Great Britain's National Institute for Health and Care Excellence (NICE) to Entyvio or vedolizumab, a biologic drug developed by Takeda for the maintenance treatment of patients with ulcerative colitis. The NICE will issue its final...

  • Novel treatment for UC at a discount.  // Gastrointestinal Nursing;Apr2015, Vol. 13 Issue 3, p12 

    The article reports that the National Institute for Health and Care Excellence has placed a condition on the use of Entyvio for the treatment of ulcerative colitis for manufacturers to offer a discount.

  • Golimumab approved for ulcerative colitis.  // WHO Drug Information;2013, Vol. 27 Issue 2, p115 

    The article reports on a 2013 decision that the U.S. Food and Drug Administration made to approve the drug golimumab to treat severe ulcerative colitis.

  • PONM12 Multifocal motor neuropathy due to infliximab. S Kelly // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe63 

    Infliximab, an anti-TNF-α monoclonal antibody has been reported to cause central demyelination. Neuropathy has occasionally been recorded. We describe multifocal motor neuropathy (MMN) in a 47-year-old man associated with infliximab treatment. A 47-year-old man presented with sub acute onset...

  • TURANDOT. Hoyle, Brian; Reinisch, Walter // MD Conference Express;Jul2015, Vol. 15 Issue 14, p10 

    A monoclonal antibody that blocks white blood cell adhesion to gut mucosal cells reduced the symptoms of moderate to severe ulcerative colitis in patients treated for 12 weeks in the randomized double-blind placebo-controlled TURANDOT trial. The antibody dose of 22.5 mg was most effective. No...

  • Non-TNF blocker for colitis, Crohn disease.  // Clinical Advisor;Jan2015, Vol. 18 Issue 1, p40 

    No abstract available.

  • Decreased renal excretion of soluble interleukin-2 receptor α after treatment with daclizumab. Meulen, Cornelis G. Ter; Göertz, Joop H.C.; Klasen, Ina S.; Verweij, Carla M.T.A.; Hilbrands, Luuk B.; Wetzels, Jack F.M.; Hoitsma, Andries J. // Kidney International;Aug2003, Vol. 64 Issue 2, p697 

    Decreased renal excretion of soluble interleukin-2 receptor α after treatment with daclizumab. Background. Daclizumab (±150 kD), a humanized monoclonal antibody (mAb) against the alpha-chain of the membrane-bound interleukin-2 (IL-2) receptor (IL-2R) also binds soluble interleukin-2R α...

  • Commentary: Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. Smith, Kendall A.; Zurawski, Gerard // Frontiers in Immunology;Sep2015, p1 

    The article explores the strategies and tactics for producing and characterizing monoclonal antibodies to human interleukin 2.

  • Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. HAHN, LINDSAY; BEGGS, ASHTON; WAHAIB, KRISTY; KODALI, LEELA; KIRKWOOD, VANESSA // American Journal of Health-System Pharmacy;8/1/2015, Vol. 72 Issue 15, p1271 

    Purpose. The pharmacology, pharmacoki-netics, safety, efficacy, and dosing recommendations of vedolizumab, an integrin-receptor antagonist for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), are reviewed. Summary. Vedolizumab is an integrin-receptor antagonist for the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics